A detailed history of Tower Research Capital LLC (Trc) transactions in Vincerx Pharma, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 6,989 shares of VINC stock, worth $1,467. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,989
Previous 7,901 11.54%
Holding current value
$1,467
Previous $6,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.51 - $0.84 $465 - $766
-912 Reduced 11.54%
6,989 $5,000
Q2 2024

Aug 13, 2024

BUY
$0.57 - $6.6 $1,915 - $22,176
3,360 Added 73.99%
7,901 $6,000
Q1 2024

May 15, 2024

SELL
$1.07 - $8.06 $864 - $6,512
-808 Reduced 15.11%
4,541 $22,000
Q4 2023

Feb 13, 2024

SELL
$0.62 - $1.18 $1,133 - $2,158
-1,829 Reduced 25.48%
5,349 $6,000
Q3 2023

Nov 14, 2023

BUY
$0.66 - $1.38 $1,983 - $4,148
3,006 Added 72.05%
7,178 $7,000
Q2 2023

Aug 14, 2023

BUY
$0.88 - $1.9 $1,075 - $2,321
1,222 Added 41.42%
4,172 $5,000
Q1 2023

May 09, 2023

BUY
$0.9 - $1.51 $260 - $436
289 Added 10.86%
2,950 $3,000
Q4 2022

Feb 10, 2023

BUY
$0.64 - $1.32 $1,676 - $3,457
2,619 Added 6235.71%
2,661 $3,000
Q3 2022

Nov 10, 2022

SELL
$0.0 - $1.72 $0 - $11,551
-6,716 Reduced 99.38%
42 $0
Q2 2022

Aug 15, 2022

BUY
$0.0 - $0.0 $0 - $0
4,292 Added 174.05%
6,758 $9,000
Q1 2022

May 12, 2022

BUY
$0.0 - $0.0 $0 - $0
1,273 Added 106.71%
2,466 $10,000
Q4 2021

Feb 14, 2022

BUY
$0.0 - $0.0 $0 - $0
576 Added 93.35%
1,193 $12,000
Q3 2021

Nov 15, 2021

BUY
$0.0 - $0.0 $0 - $0
584 Added 1769.7%
617 $10,000
Q2 2021

Aug 16, 2021

SELL
$0.0 - $27.0 $0 - $3,645
-135 Reduced 80.36%
33 $0
Q1 2021

May 17, 2021

BUY
$22.6 - $31.0 $3,796 - $5,208
168 New
168 $3,000

Others Institutions Holding VINC

About Vincerx Pharma, Inc.


  • Ticker VINC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,189,800
  • Market Cap $4.45M
  • Description
  • Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...
More about VINC
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.